Tech Company Financing Transactions

Crossbow Therapeutics Funding Round

On 7/11/2023, Crossbow Therapeutics raised $80 million in Series A investment from MPM Capital, Pfizer Venture Investments and BVF Partners.

Transaction Overview

Announced On
7/11/2023
Transaction Type
Venture Equity
Amount
$80,000,000
Round
Series A
Proceeds Purpose
The company intends to use the funds to advance the development of novel therapies that potently target peptide-loaded major histocompatibility complexes (pMHCs) on cancer cells, using antibodies that mimic T-cell receptors (TCR-mimetics).

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1030 Massachusetts Ave. 210
Cambridge, MA 02138
USA
Email Address
Overview
Crossbow Therapeutics, Inc., is a biotechnology company determined to improve the lives of people with cancer by unlocking the therapeutic potential of T-cell receptor (TCR)-mimetic antibodies. The company's T-Bolt� therapies are next-generation, easily assembled immunotherapies directed with high precision at previously unreachable cancer cell targets. Crossbow's efficient and selective approach is designed to target the entire universe of cancer proteins, dramatically expanding the potential of antibody therapy to address many types of cancer.
Profile
Crossbow Therapeutics LinkedIn Company Profile
Social Media
Crossbow Therapeutics Company Twitter Account
Company News
Crossbow Therapeutics News
Facebook
Crossbow Therapeutics on Facebook
YouTube
Crossbow Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Briggs Morrison
  Briggs Morrison LinkedIn Profile  Briggs Morrison Twitter Account  Briggs Morrison News  Briggs Morrison on Facebook
Chief Scientific Officer
Dmitri Wiederschain
  Dmitri Wiederschain LinkedIn Profile  Dmitri Wiederschain Twitter Account  Dmitri Wiederschain News  Dmitri Wiederschain on Facebook
Co-Founder
Geraldine Paulus
  Geraldine Paulus LinkedIn Profile  Geraldine Paulus Twitter Account  Geraldine Paulus News  Geraldine Paulus on Facebook


 

 

Browse more venture capital transactions:

Prev: 7/11/2023: CoJourney venture capital transaction
Next: 7/11/2023: finres venture capital transaction

 

Share this article

 


Where The Data Comes From

Our team works diligently to report on funding rounds that are announced publicly. VC investment data records reported here are sourced from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary